News

Tardive dyskinesia (TD) remains a common long-term consequence of prolonged exposure to dopamine receptor-blocking agents, particularl

We want to hear from you! Please take a few minutes to complete our brief survey and share your feedback — your input directly shapes the content and experience we deliver.

A new educational quiz from Psych Congress Network highlights the importance of evaluating potential drug-drug interactions

A real-world claims analysis found that adults with tard

A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of

Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, vesicular monoamine transporter type 2 (VMAT2), in functional assessments of the drug’s deuterate

Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according

The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of 

Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both p